CRINETICS PHARMACEUTICALS, INC.

Basic Information

6197 Cornerstone Ct, Suite111
SAN DIEGO, CA, 92121-4718

Company Profile

n/a

Additional Details

Field Value
DUNS: 828902515
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Nonpeptide Kisspeptin Antagonists for PCOS and HPG axis control

    Amount: $783,766.00

    DESCRIPTION provided by applicant During the past decade the discovery of kisspeptin peptides and their cognate receptor KISS R has expanded our mechanistic understanding of the hypthothalamic pit ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  2. Small molecule somatostatin agonists for neuropathic pain

    Amount: $326,121.00

    DESCRIPTION provided by applicant Somatostatins are neuropeptides originally discovered to inhibit growth hormone secretion by the pituitary The actions of somatostatins are mediated by five relat ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  3. Peripheral administration of nonpeptide somatostatin agonists for ophthalmic dise

    Amount: $224,092.00

    Project Summary With an increasing older population, including the generational aging of the baby boomers , age-related eye diseases are common and becoming more prevalent. Currently, it is estimated ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists

    Amount: $2,162,550.00

    DESCRIPTION (provided by applicant): Neuropeptide somatostatin analogs are important therapeutics for the treatment of hormone secreting tumors with annual sales of ~ 1.7B. However, the currently avai ...

    SBIR Phase II 2013 Department of Health and Human Services
  5. Nonpeptide Kisspeptin Antagonists for PCOS and HPG axis control

    Amount: $296,283.00

    DESCRIPTION (provided by applicant): During the past decade, the discovery of kisspeptin peptides and their cognate receptor KISS1R (aka GPR54) has expanded our mechanistic understanding of the hyptho ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists

    Amount: $282,070.00

    DESCRIPTION (provided by applicant): Analogs of the neuropeptide somatostatin are important therapeutics for the treatment of hormone secreting tumors with annual sales in excess of 1.3B. However, cu ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. Biosensors of GPCR Activation and Inhibition for Drug Discovery

    Amount: $237,895.00

    DESCRIPTION (provided by applicant): Measurements of the affinity, potency and efficacy of ligands to G protein-coupled receptors (GPCRs) are fundamental to pharmacology and drug discovery. Cellular f ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government